Arrowhead Pharmaceuticals Inc (ARWR)
Debt-to-assets ratio
| Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | 393,183 | 0 | — | — | — |
| Total assets | US$ in thousands | 1,139,800 | 765,552 | 691,939 | 710,148 | 522,504 |
| Debt-to-assets ratio | 0.34 | 0.00 | 0.00 | 0.00 | 0.00 |
September 30, 2024 calculation
Debt-to-assets ratio = Long-term debt ÷ Total assets
= $393,183K ÷ $1,139,800K
= 0.34
The debt-to-assets ratio of Arrowhead Pharmaceuticals Inc has shown a notable increase from 0.00 in the fiscal years ended September 30, 2020, 2021, and 2022 to 0.34 as of September 30, 2024. This indicates that the company has taken on debt in relation to its total assets, with a higher proportion of assets being funded by debt in the most recent year.
The sudden appearance of a debt-to-assets ratio in 2024 suggests that Arrowhead Pharmaceuticals Inc may have leveraged its balance sheet to finance its operations, investments, or acquisitions. A ratio of 0.34 indicates that approximately 34% of the company's assets are financed by debt as of September 30, 2024.
It would be essential for stakeholders and investors to closely monitor how Arrowhead Pharmaceuticals Inc manages its debt levels and assess whether the increase in the debt-to-assets ratio aligns with the company's growth strategies and financial health.
Peer comparison
Sep 30, 2024